Portola Pharmaceuticals

Portola discovers and develops innovative therapeutics based on targets with established proof of concept that are designed to provide significant advances over current treatments for cardiovascular disease and autoimmune/inflammatory diseases. Portola scientists have successfully collaborated for over 15 years on the discovery and development of novel small molecule agents targeting platelets, coagulation pathways and protein kinases. Our team was instrumental in the discovery, development and commercialization of the leading GP IIb-IIIa inhibitor, INTEGRILIN® (eptifibatide). Portola's pipeline ...


There are no scholarships at this time


There are no events at this time

Company Data on Portola Pharmaceuticals
provided by Owler


Portola Pharmaceuticals is hiring for these positions

Show me: All available jobs